Reversing the multidrug resistance in acute leukemia: Until the leukemia initiating cell?

Abstract Reversal of drug resistance is of pivotal importance in order to improve the results of chemotherapy. Monitoring of such reversal is necessary in order to analyze the results of clinical trials. Nonetheless, the leukemia cell population to eradicate is the leukemia initiating cells characte...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2009-06, Vol.33 (6), p.749-749
Main Author: Costello, Régis T
Format: Article
Language:English
Subjects:
ADP-ribosyl Cyclase 1 - immunology
Antigens, CD34 - immunology
ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors
CD34+CD38
Dibenzocycloheptenes - pharmacology
Dibenzocycloheptenes - therapeutic use
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Hematology, Oncology and Palliative Medicine
Humans
Leukemia - drug therapy
Leukemia - immunology
Leukemia - pathology
Leukemia initiating cell
Multidrug resistance
Quinolines - pharmacology
Quinolines - therapeutic use
Tumor escape
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Reversal of drug resistance is of pivotal importance in order to improve the results of chemotherapy. Monitoring of such reversal is necessary in order to analyze the results of clinical trials. Nonetheless, the leukemia cell population to eradicate is the leukemia initiating cells characterized by a CD34+CD38− phenotype. The evaluation of novel drug resistance modulators should be performed both in the whole leukemic cell population and in the leukemia initiating cell compartment, that is responsible for “mature” leukemia cells replenishment.
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2008.09.022